Gain Therapeutics (GANX) Current Leases (2020 - 2025)
Historic Current Leases for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $115910.0.
- Gain Therapeutics' Current Leases fell 3516.65% to $115910.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $115910.0, marking a year-over-year decrease of 3516.65%. This contributed to the annual value of $160913.0 for FY2024, which is 2994.43% down from last year.
- Per Gain Therapeutics' latest filing, its Current Leases stood at $115910.0 for Q3 2025, which was down 3516.65% from $136320.0 recorded in Q2 2025.
- Gain Therapeutics' 5-year Current Leases high stood at $235798.0 for Q2 2023, and its period low was $115910.0 during Q3 2025.
- Over the past 5 years, Gain Therapeutics' median Current Leases value was $204569.0 (recorded in 2024), while the average stood at $191368.7.
- In the last 5 years, Gain Therapeutics' Current Leases surged by 8322.26% in 2022 and then plummeted by 3516.65% in 2025.
- Gain Therapeutics' Current Leases (Quarter) stood at $219137.0 in 2021, then rose by 4.54% to $229080.0 in 2022, then grew by 0.27% to $229693.0 in 2023, then fell by 29.94% to $160913.0 in 2024, then decreased by 27.97% to $115910.0 in 2025.
- Its Current Leases was $115910.0 in Q3 2025, compared to $136320.0 in Q2 2025 and $148674.0 in Q1 2025.